CASI Pharmaceuticals has completed its redomiciliation merger to become a Cayman Islands company. As a result of the merger, each outstanding share of the common stock of the company was converted into the right to receive one ordinary share of CASI Pharmaceuticals, Inc., a Cayman Islands company. The ordinary shares of CASI Cayman will continue to be listed on the NASDAQ Capital Market under the same trading symbol “CASI” that was used for the common stock of the company. CASI is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products.
CASI Pharmaceuticals, Inc. (NASDAQ: CASI) (“CASI” or the “Company”), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that the redomiciliation merger to redomicile the Company as a Cayman Islands company (the “Redomiciliation Merger”) has been completed.
Pursuant to the Redomiciliation Merger, each outstanding share of the common stock of the Company was converted into the right to receive one ordinary share of CASI Pharmaceuticals, Inc., a company incorporated under the laws of the Cayman Islands (“CASI Cayman”). The ordinary shares of CASI Cayman will be listed on the NASDAQ Capital Market under the trading symbol “CASI,” the same symbol under which the common stock of the Company was listed.
Source: BioSpace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
